38 reports

  • CPL-50003602 - Drug Profile
  • CPL-50003602 - Drug Profile

cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2018 Summary cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase...

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • CPL-50003602 - Drug Profile
  • PHASE II - TRIAL DETAILS

cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H1 2018 Summary cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase...

  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative

Its products are indicated for the treatment of diseases such as Alzheimer' s disease, depression, Parkinson' s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington' s disease, among others.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company Financials
  • Acorda Therapeutics, Inc.
  • CPL-50003602 - Drug Profile

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H1 2017 Summary cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC...

  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative

Patients are randomized ##:## to placebo or SYN## dosed once daily over a ## week treatment period.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company
  • Biotie Therapies Corp.
  • Target
  • Clinical Trial profile. 41 Trial Title

Schizoaffective Disorder Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Schizoaffective Disorder Global Clinical Trials Review, H2, 2018" provides an overview of Schizoaffective Disorder clinical trials scenario.This report provides top line data relating to...

  • Antipsychotic
  • Clinical Trial
  • Psychotic Disorder
  • Therapy
  • World

The disorder can be BIPOLAR DISORDER divided into two types: bipolar disorder type I, characterized by at least one episode of mania with or without a depressive episode, whereas the bipolar disorder type II is characterized by at least one hypom

  • Psychotic Disorder
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • SERX-480 - DRUG PROFILE

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H2 2017 Summary According to the recently published report ’5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2017’; 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline...

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Reviva Pharmaceuticals Inc.
  • SMALL MOLECULES TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE
  • Licensing and Collaboration

Schizophrenia - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2018, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape. Schizophrenia is a chronic,...

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Company
  • Product Initiative
  • Clinical Trial profile. 274 Trial Title
  • Clinical Trial profile. 171 Trial Title

Psychosis Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Psychosis Global Clinical Trials Review, H1, 2018" provides an overview of Psychosis clinical trials scenario.This report provides top line data relating to the clinical trials on Psychosis. Report...

  • Antipsychotic
  • Clinical Trial
  • Psychotic Disorder
  • Therapy
  • World

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • OTC
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd
  • Schizophrenia, Global, Key Features of Tau Protein
  • Schizophrenia, Global, Evidence for Tau Protein (MAPT) as a Therapeutic Target, 2018

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia is a severe chronic mental disorder affecting a person’s mental, emotional and physical wellbeing. Patients appear out of touch with reality, preventing...

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • World
  • Deals & Alliance
  • SMALL MOLECULES TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE
  • SMALL MOLECULE TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE

Schizophrenia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H1 2018, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape. Schizophrenia is a chronic,...

  • Mental Health
  • Psychotic Disorder
  • United States
  • Company
  • Omeros Corporation
  • CPL-50003602 - DRUG PROFILE

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase...

  • Psychotic Disorder
  • Therapy
  • United States
  • World
  • Pfizer Inc.

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd
  • 2.4 FORECAST METHODOLOGY
  • 2.2 RISK FACTORS AND COMORBIDITIES

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025 Summary Schizophrenia is a severe mental disorder that affects an individual’s behaviors, thoughts, and emotions; it is extremely heterogeneous, and no two affected individuals have the same experience (Buckley et al., 2009). The disorder is characterized by...

  • Psychotic Disorder
  • Japan
  • United Kingdom
  • United States
  • Forecast
  • R&D Progress Research and Development Brief

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018 Summary According to the recently published report ’5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2018’; 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline...

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Reviva Pharmaceuticals Inc.
  • glycemic control.
  • lurasidone hydrochloride - Drug Profile

Adverse events associated with SEROQUEL XR (greater than or equal to ##%) included schizophrenia, headache, insomnia, psychotic disorder, increased weight and agitation.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative

The number of people suffering from psychotic disorders is also rising in India.

  • Psychotic Disorder
  • North America
  • United States
  • World
  • Market Size
  • SMALL MOLECULE TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides an overview of the Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline landscape. Bipolar...

  • Bipolar Disorder
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Intra-Cellular Therapies, Inc.
  • Apr 25, 2018: How the brain is folded provides researchers with an accurate marker to predict psychosis in high-risk patients
  • Mar 05, 2018: Early psychosis programs significantly reduce patient mortality, study finds

Summary Lawson Health Research Institute (Lawson) is a hospital-based research institute that offers educational and research programs.The institute’ services include health research programs, medical research programs, educational research programs, scientific research programs, patient care services, medical care, clinical...

  • Healthcare
  • Psychotic Disorder
  • Canada
  • Company
  • Deals & Alliance
  • Apr 25, 2018: How the brain is folded provides researchers with an accurate marker to predict psychosis in high-risk patients
  • Mar 05, 2018: Early psychosis programs significantly reduce patient mortality, study finds

Summary Western University is a research university that provides undergraduate and postgraduate courses and research services.The university provides courses in arts and humanities, music, medicine and dentistry, science, social science, information and media studies, law and business management, among others. Western...

  • Healthcare
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • Canada

STUDY DESIGN Aripiprazole is an atypical antipsychotic and the active ingredient in Abilify®, a leading medication in the US used for the treatment of a number of psychiatric disorders including bipolar I disorder, schizophrenia, major depressive disorder and irri

  • Clinical Trial
  • Psychotic Disorder
  • United States
  • Company
  • Aequus Pharmaceuticals Inc.
  • 4.4 FORECAST METHODOLOGY
  • and Figure 2 present the number of 12-month diagnosed prevalent cases of schizophrenia

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and...

  • Psychotic Disorder
  • Alkermes plc
  • Janssen Biotech, Inc.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • H. LUNDBECK A/S: MAJOR PRODUCTS AND SERVICES

H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report Summary H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing...

  • Psychotic Disorder
  • Europe
  • United States
  • Company
  • H. Lundbeck A/S
  • 6.3 Lundbeck

It targets mood disorders including (depression, anxiety), psychotic disorders (schizophrenia, maniac episodes), alcohol dependency, epilepsy, as well as Alzheimer' s and Parkinson' s disease.

  • Psychotic Disorder
  • United States
  • World
  • Market Size
  • Lundbeck Inc.
  • Stages of the course of schizophrenia
  • REFERENCES

Lifetime prevalence of psychotic and bipolar I disorders in a general population.

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Northern Europe
  • Western Europe
  • evenamide - Drug Profile

Psychotic symptoms include disorganized thought, speech or behavior, disordered thinking (jumping between unrelated topics, making strange connections between thoughts), Catatonia (unresponsiveness).

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • ACADIA Pharmaceuticals Inc.